Data Meets Decision: Expert Approaches to Perioperative Immunotherapy in LA HNSCC
Multiple dates available
Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
Ticiana Leal, MD
The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
Neal Ready, MD, PhD
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
From Data to Decision: Patient Selection and Real-World Application
Christophe Le Tourneau, MD, PhD
Marc Oliva, MD, PhD
The Evidence Base: Key Trials and Emerging Data
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
Precision in Practice—Bringing Targeted Therapy to mHSPC
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Javier Cortes, MD, PhD
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
What’s Next for TROP2-Directed ADCs in TNBC?
Tiffany Traina, MD
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Susana Campos, MD, MPH
Robert Coleman, MD, FACOG
Debra Richardson, MD
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.